Nowadays cancer immunotherapy, such as immune checkpoint inhibitors (ICBs) targeting cytotoxic T-lymphocyte associated antigen 4, programmed cell death 1 (PD-1), and programmed death ligand 1 (PD-L1), has revolutionized the treatments of a variety of different cancers, including lung cancer. This evidence concerns the gene CD274 and lung cancer.